"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04594850","Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously","Cellgram-ED","Recruiting","No Results Available","Erectile Dysfunction","Biological: Cellgram-ED","The amount of change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value|Changes in SEP Q 2 and Q 3 evaluation after administration of investigational drug compared to baseline|Global Assessment Question (GAQ) evaluation after administration of investigational drugs|Changes in Penile Doppler Sonography(PDS) level after administration of clinical trial drug compared to baseline","Pharmicell Co., Ltd.","Male","19 Years to 79 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PMC-P-10","October 19, 2020","October 31, 2023","October 31, 2023","October 20, 2020",,"October 26, 2020","Asan medical center, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|Seoul ST. Mary's hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04594850"
2,"NCT02344849","Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: mesenchymal stem cell","Number and severity of adverse events|Change From Baseline in the International Index of Erectile Function(IIEF)|Penile Doppler Sonography, PDS|Change From Baseline in Sexual Encounter Profile (SEP) Question 2|Global Assessment Question (GAQ)","Pharmicell Co., Ltd.","Male","20 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellgram-ED","July 2015","January 31, 2018","April 2018","January 26, 2015",,"January 9, 2019","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02344849"
